• Price (USD)304.71
  • Today's Change-12.57 / -3.96%
  • Shares traded432.34k
  • 1 Year change+20.17%
  • Beta0.4593
Data delayed at least 15 minutes, as of Feb 02 2023 15:51 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF) and it has several ongoing clinical and research programs to advance and extend treatment of CF. The Company's marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Its four medicines are being used to treat the people with CF in North America, Europe and Australia. The Company has a pipeline of investigational therapies in other serious diseases where it is leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. The Company’s other pipeline products include CTX001, VX-147, VX-121, VX-561, VX-548, and VX-880.

  • Revenue in USD (TTM)8.70bn
  • Net income in USD3.27bn
  • Incorporated1989
  • Employees3.90k
  • Location
    Vertex Pharmaceuticals Inc50 Northern AvenueBOSTON 02210United StatesUSA
  • Phone+1 (617) 341-6393
  • Websitehttps://www.vrtx.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
VRTX:NSQ since
ViaCyte IncAnnounced11 Jul 202211 Jul 2022Announced3.54%320.00m
Catalyst Biosciences Inc-Complement PortfolioAnnounced23 May 202223 May 2022Announced17.83%60.00m
Data delayed at least 15 minutes, as of Feb 02 2023 15:51 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Iqvia Holdings Inc14.31bn1.18bn43.37bn85.00k38.008.1119.473.036.156.1574.4328.780.593--5.76181,101.304.941.776.252.1434.7234.308.343.64--5.160.69860.0022.1415.28246.2468.0831.30--
Moderna Inc21.39bn11.77bn66.96bn2.70k6.303.755.533.1327.6527.6550.6946.490.91062.937.337,922,222.0050.0941.1777.8866.7879.20--55.0052.351.80--0.05990.002,199.12179.441,733.33--53.67--
Zoetis Inc8.01bn2.07bn78.21bn12.10k38.3516.7930.959.774.384.3816.9410.000.58491.146.84661,735.6015.0813.7917.9316.0470.1968.7525.7823.941.4812.190.584722.5316.499.7324.3619.9317.1720.72
Vertex Pharmaceuticals Incorporated8.70bn3.27bn81.44bn3.90k25.046.2523.839.3612.6712.6733.6950.770.59342.897.002,230,913.0022.3218.0126.4021.8788.0087.7737.6229.174.5532.160.03280.0022.0634.79-13.63--32.96--
Regeneron Pharmaceuticals Inc13.71bn5.37bn82.55bn10.37k15.993.8514.486.0247.4047.40120.98197.050.5340.89672.491,322,357.0020.9225.6424.0029.9985.3988.5139.1739.114.5220.540.1119--89.1427.02129.8655.241.52--
Gilead Sciences, Inc.27.14bn3.33bn105.36bn14.40k31.775.0019.443.882.642.6421.5216.810.41864.396.081,884,445.005.108.356.0710.0274.6279.5612.1922.221.165.860.54558.7610.60-2.124,960.98-14.34-4.999.07
Data as of Feb 02 2023. Currency figures normalised to Vertex Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

42.47%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 202220.07m7.82%
BlackRock Fund Advisorsas of 30 Sep 202216.09m6.27%
Fidelity Management & Research Co. LLCas of 30 Sep 202215.67m6.11%
Capital Research & Management Co. (World Investors)as of 30 Sep 202212.52m4.88%
SSgA Funds Management, Inc.as of 30 Sep 202212.29m4.79%
AllianceBernstein LPas of 30 Sep 20229.15m3.56%
Wellington Management Co. LLPas of 30 Sep 20228.03m3.13%
Geode Capital Management LLCas of 30 Sep 20225.27m2.05%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 20225.16m2.01%
Jennison Associates LLCas of 30 Sep 20224.76m1.85%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.